Literature DB >> 2703009

Phase II study of high-dose 4'-epidoxorubicin in the treatment of advanced gastrointestinal cancer.

D A Vorobiof1, G Falkson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703009     DOI: 10.1016/0277-5379(89)90271-x

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


× No keyword cloud information.
  2 in total

Review 1.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

2.  Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer.

Authors:  S-H Lee; W K Kang; J Park; H Y Kim; J H Kim; S I Lee; J O Park; K Kim; C W Jung; Y S Park; Y-H Im; M H Lee; K Park
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.